Ardelyx Inc.

5.04
0.13 (2.65%)
At close: Jan 22, 2025, 3:59 PM
5.30
5.05%
After-hours Jan 22, 2025, 07:05 PM EST
undefined%
Bid 5.28
Market Cap 1.19B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.32
PE Ratio (ttm) -15.77
Forward PE n/a
Analyst Buy
Ask 5.3
Volume 4,623,360
Avg. Volume (20D) 4,900,056
Open 4.88
Previous Close 4.91
Day's Range 4.88 - 5.19
52-Week Range 4.32 - 10.13
Beta undefined

About ARDX

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult pat...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2014
Employees 267
Stock Exchange NASDAQ
Ticker Symbol ARDX

Analyst Forecast

According to 7 analyst ratings, the average rating for ARDX stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 108.13% from the latest price.

Buy 85.71%
Hold 14.29%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Ardelyx Inc. is scheduled to release its earnings on Feb 20, 2025, during market hours.
Analysts project revenue of $108.57M, reflecting a 215.95% YoY growth and earnings per share of -0.01, making a -91.67% decrease YoY.
1 week ago
+15.98%
Ardelyx shares are trading higher after the compan... Unlock content with Pro Subscription
5 months ago
+10%
Ardelyx shares are trading higher after the company reported better-than-expected Q2 financial results.